Novel multi-targeted inhibitors suppress ocular neovascularization by regulating unique gene sets

Area of Science:

• Biomedical research
• Molecular biology
• Drug discovery

Background:

• Neovascular diseases, including cancers and ocular disorders, pose significant health risks.
• Current anti-vascular endothelial growth factor A (VEGF-A) therapies face challenges with patient responsiveness and drug resistance.
• Previous combination therapies targeting VEGF-A and platelet-derived growth factor B (PDGF-B) were limited by incomplete inhibition of related growth factors.

Purpose of the Study:

• To design and evaluate novel multi-targeted inhibitors capable of blocking multiple VEGF and PDGF family members simultaneously.
• To assess the efficacy of these inhibitors in suppressing cellular processes involved in neovascularization.
• To investigate the therapeutic potential of these inhibitors in an in vivo model of ocular neovascularization.

Main Methods:

• Development of a fusion protein incorporating ligand-binding domains of vascular endothelial growth factor receptor 1 (VEGFR1), VEGFR2, and platelet-derived growth factor receptor beta (PDGFRβ) to act as a decoy blocker.
• In vitro assessment of inhibitor effects on vascular endothelial cell and smooth muscle cell migration and proliferation, and receptor activation.
• In vivo evaluation in a choroidal neovascularization model to compare efficacy against monotherapies.
• Genome-wide microarray analysis to identify unique gene expression patterns regulated by the multi-targeted inhibitor.

Main Results:

• The novel inhibitors effectively suppressed migration and proliferation of vascular and smooth muscle cells in vitro.
• In vitro studies confirmed the abolition of VEGFR2 and PDGFRβ activation.
• In vivo, the multi-targeted inhibitor demonstrated superior efficacy in inhibiting ocular neovascularization compared to individual VEGFR or PDGFR inhibitors.
• Microarray analysis revealed that the multi-targeted inhibitor regulated distinct gene sets compared to monotherapies, highlighting its unique mechanism.

Conclusions:

• Simultaneous blockade of VEGFR1, VEGFR2, and PDGFRβ using multi-targeted inhibitors is a more effective strategy than monotherapy for suppressing pathological angiogenesis.
• These novel inhibitors exhibit promising therapeutic potential for treating neovascular diseases.
• The unique gene regulation profile underscores the functional superiority of the multi-targeted approach.